In vitro biomarker discovery in the parasitic flatworm Fasciola hepatica for monitoring chemotherapeutic treatment  by Morphew, Russell M. et al.
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The parasitic ﬂatworm Fasciola hepatica is a global food security risk. With no vaccines, the
sustainability of triclabendazole (TCBZ) is threatened by emerging resistance. F. hepatica
excretory/secretory (ES) products can be detected in host faeces and used to estimate TCBZ
success and failure. However, there are no faecal based molecular diagnostics dedicated to
assessing drug failure or resistance to TCBZ in the ﬁeld. Utilising in vitro maintenance and
sub-proteomic approaches two TCBZ stress ES protein response ﬁngerprints were identi-
ﬁed: markers of non-killing and lethal doses. This study provides candidate protein/peptideeywords:
roteomics
iomarkers
biomarkers to validate for detection of TCBZ failure and resistance.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).
derivative, which shows activity against both pathogenic
juvenile and mature ﬂukes. TCBZ has been the mainstay ofriclabendazole
alreticulin
.  Introduction
he liver ﬂuke, Fasciola hepatica, is an invasive parasitic trema-
ode causing both acute and chronic disease. Liver ﬂuke is a
ood security risk causing annual losses of more  than US$3000
illion to livestock production worldwide through livestock
ortality and by decreased productivity via reduction of milk,
ool and meat yields [1]. Further impacts on cattle productiv-
ty result from a negative association between the exposure
o F. hepatica and the diagnosis of Bovine tuberculosis [2].
Abbreviations: TCBZ, triclabendazole; TCBZ-SO, triclabendazole
ory/secretory; Con, control dose of triclabendazole (0 g/ml); SL, s
riclabendazole (50 g/ml); CRT, calreticulin; Cat L, cathepsin L.
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212-9685/© 2014 The Authors. Published by Elsevier B.V. on behalf of
rticle  under the CC BY-NC-SA license (http://creativecommons.org/licF. hepatica is also responsible for human food borne disease as
an emerging worldwide zoonosis, with nearly 180 million peo-
ple at risk [3]. In the absence of commercial vaccines, control
of fascioliasis in livestock is mostly based on treatment with
anthelmintic drugs. The current drug of choice for treatment
of fascioliasis is triclabendazole (TCBZ), a benzimidazole- sulphoxide; TCBZ-R, triclabendazole resistance; ES, excre-
ub-lethal dose of triclabendazole (15 g/ml); L, lethal dose of
ﬂukicides for Fasciola control for more  than 20 years [4]. How-
ever, TCBZ control of F. hepatica may have been compromised
 European Proteomics Association (EuPA). This is an open access
enses/by-nc-sa/3.0/).
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previously described [21]. Brieﬂy, samples were centrifuged
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with the apparent emergence of TCBZ resistance (TCBZ-R),
ﬁrst encountered in Australia [5] and since reported pan
Europe [see 6]. Current suggested resistance levels may be
exacerbated following the end of patent protection leading
to generic forms of TCBZ for wider application and potential
misuse. Furthermore, poor on-farm management of TCBZ
dosing or poor host metabolism of TCBZ would mimic  and
ultimately simulate TCBZ resistance if parasites are exposed
to sub-optimal drug levels. In addition, infection from the
non-pathogenic but widespread rumen ﬂuke also interferes
with resistance monitoring of liver ﬂuke; eggs are visually
similar and generate false-positives on resistance testing
by routine faecal egg count reduction tests. Thus, species
speciﬁc markers for liver ﬂuke following drug exposure are
required for appropriate control [7].
There is a wealth of research dedicated to further under-
standing the mode of action of TCBZ but the multifaceted
and highly complex mechanisms are yet to be resolved at
the molecular level [8]. For example, laboratory reported
effects of TCBZ on liver ﬂuke include tegumental disruption
through inhibition of tegumental secretory body movement
[9–11], disruption of egg formation via mitotic inhibition of
vitelline cells [12], apoptosis in the testes, ovary and vitelline
follicles [13], inhibition of protein synthesis [14] and the
stimulation of glucose-derived acetate and propionate [15].
Host and parasite biotransformation of TCBZ further com-
plicate attempts to understand TCBZ mode of action [16].
TCBZ is, primarily oxidised by the host liver into the major
active metabolite, triclabendazole sulphoxide (TCBZ-SO) via
the ﬂavin monooxygenase pathway and cytochrome P450
[17,18]. Further metabolism yields levels of triclabendazole
sulphone (TCBZ-SO2), a potent ﬂukicide in its own right [9]
and hydroxylated metabolites (OH-TCBZ, OH-TCBZ-SO and
OH-TCBZ-SO2) [19].
Our hypothesis is that, due to its multiple effects on
parasite metabolism, TCBZ treatment will leave measurable
protein signatures in the host environment when the par-
asite is successfully killed or the parasite is resistant to
the drug or a sub-lethal drug failure is occurring. Previous
antibody based studies have showed that liver ﬂuke pro-
tein products survive the passage via host intestine and
can subsequently be detected in host faeces [20]. Our pre-
vious proteomics studies also directly detected liver ﬂuke
proteins in host bile [21]. Therefore, proteomics supported by
genomic/transcriptomic databases, in principle, can provide
the detailed drug response information required to develop
new ﬁeld based tests.
Moreover, a current molecular test for indicating the pres-
ence of liver ﬂuke infection operates on this basis i.e. the
release of parasite proteins can be detected in host faeces
(BioK antigen detection kit, BioX Diagnostics). Therefore, drug
induced, released ES products will provide us with a suite
of proteins speciﬁcally associated with successful or failed
drug treatment that may be detectable in the host faeces.
New approaches are needed to support liver ﬂuke manage-
ment, especially given the continued absence of commercial
vaccines, apparent ﬂuke resistance to TCBZ, interference by
rumen ﬂuke on monitoring liver ﬂuke, no chemical treatments
available for snail control, a limited opportunity to move live-
stock to un-parasitised land and the cost and limitations of s 3 ( 2 0 1 4 ) 85–99
drainage opportunities to remove a mobile aquatic intermedi-
ate stage.
Proteomics offers the opportunity to identify biomarker
panels for monitoring anthelmintic efﬁciency in the ﬁeld [22].
Therefore, we have taken a proteomic lead strategy to develop
a biomarker panel for TCBZ-SO response in F. hepatica. We
aimed to determine the protein complement released from
adult F. hepatica during TCBZ-SO exposure which will poten-
tially be shed from the host via the faeces. From this approach
a potential set of biomarkers for assessing anthelmintic
TCBZ/TCBZ-SO treatment will be generated and our under-
standing of the mode of action of TCBZ-SO could also be
enhanced. We incorporate proteomics to delineate the excre-
tory/secretory products of naturally infected adult F. hepatica
released during in vitro maintenance under TCBZ-SO expo-
sure using 2-DE, mass spectrometry and bioinformatics as a
chemotherapy case study.
2.  Materials  and  methods
2.1.  ES  product  collection:  in  vitro  maintenance
Live adult F. hepatica from natural infections were collected
from the livers and bile ducts of newly slaughtered sheep
at a local collaborating abattoir and immediately washed in
PBS at 37 ◦C. Fluke were pooled and washed for 1 h with PBS
replacement every 15 min. Post-washes, replicates of 10 adult,
sized matched, worms were placed into ﬂuke DME  culture
media containing 15 mM HEPES, 61 mM glucose, 2.2 mM Cal-
cium acetate, 2.7 mM Magnesium sulphate, 1 M serotonin
and gentamycin (5 g/ml) as previously described [23]. Main-
tenance cultures were allowed to incubate at 37 ◦C for 2 h
(including transport to the proteomics laboratory) to estab-
lish a baseline protein proﬁle. Upon completion of the initial
2 h incubation, culture media was replaced and supplemented
with TCBZ-SO (LGC Standards, UK) at 50 g/ml (lethal dose) or
15 g/ml (sub-lethal dose) in DMSO (ﬁnal conc. 0.1%, v/v). For
control samples only DMSO was added to a ﬁnal volume of
0.1% (v/v). Fluke maintenance cultures were allowed to incu-
bate at 37 ◦C for a 6 h time period after which the media was
refreshed, containing DMSO and TCBZ-SO at same concen-
tration if required. Fluke maintenance cultures were allowed
to incubate at 37 ◦C for a further 6 h. A ﬁnal refreshment of
culture media was conducted and ﬂuke maintenance cultures
allowed to incubate for an additional 12 h at 37 ◦C. Upon com-
pletion of the maintenance culture, ﬂuke were removed from
the media and snap frozen individually in liquid N2. Protease
inhibitors (CompleteMini, Roche, UK) were added to all media,
after the allotted incubation, and immediately snap frozen
in liquid N2 prior to preparation for proteomic analysis. All
samples were stored at −80 ◦C.
2.2.  Preparation  and  2D  proteomics
Collected ES products from pooled samples were prepared asat 45,000 × g for 30 min  at 4 C and the supernatants precip-
itated using 20% TCA/acetone, w/v. Samples prepared for
2D SDS-PAGE were re-solubilised in buffer containing 8 M
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rea, 2% CHAPS, w/v, 33 mM DTT, 0.5% carrier ampholytes
pH 3–10) (v/v) and protease inhibitors (CompleteMini, Roche,
K). A total of 300 l containing 100 g of ES product samples
ere used to actively rehydrate and focus 17 cm linear pH
–10 IPG strips (Biorad, UK) at 20 ◦C for separation in the ﬁrst
imension. All IPG strips were focussed between 60,000 and
5,000 Vh using the Protean IEF Cell (Biorad, UK). Each IPG
trip was equilibrated for 15 min  in 5 ml  of equilibration buffer
containing 50 mM Tris–HCl pH 8.8, 6 M urea, 30% glycerol
v/v) and 2% SDS (w/v) [24]) with the addition of DTT (Melford,
K) at 10 mg/ml  followed by a second equilibration with IAA
Sigma, UK) at 25 mg/ml  replacing DTT. The IPG strips were
eparated in the second dimension on the Protean II system
Biorad, UK) using 12.5% polyacrylamide gels and run at 40 mA
or approximately 1 h until through the stacking gel followed
y 60 mA  through the resolving gel until completion.
Gels were Coomassie blue stained (PhastGel Blue R, Amer-
ham Biosciences, UK) and imaged with a GS-800 calibrated
ensitometer (Biorad, UK). Imaged 2-DE gels were analysed
sing Progenesis PG220 v.2006. Analysis was performed using
ode of non-spot background subtraction on average gels cre-
ted from a minimum of ﬁve biological replicates. Normalised
pot volumes were calculated using the Progenesis ‘total
pot volume multiplied by total area’ normalisation method.
hese normalised volumes were used to determine the degree
f protein abundance change, up and/or down, between
omparisons (with signiﬁcance set at ±2-fold change). Signif-
cance of fold changes was conﬁrmed by a one way ANOVA
sing LOG10 transformation, where appropriate, following a
olmogorov–Smirnov test for normally distributed spot vol-
mes. Unmatched protein spots were also detected between
el comparisons. Key protein spots of interest were excised
nd tryptically digested (modiﬁed trypsin sequencing grade,
oche, UK).
Protein spot data was taken from Progenesis and used for
andom forests (RF) analysis, an ensemble learning algorithm
reiman [25] as previously described [26]. RF analysis was per-
ormed using random-Forest (R software for random forest).
otal protein secreted by each treatment was also recoded and
as analysed by a two way ANOVA.
.3.  Spot  excision  and  in-gel  tryptic  digestion
rotein spots were manually excised from SDS-PAGE and
igested as previously described [23]. Brieﬂy, excised protein
pots were destained in 50% (v/v) acetonitrile (ACN) and 50 mM
mmonium bicarbonate overnight at 4 ◦C until clear. Prior to
igestion, protein spots were dehydrated in 100% ACN at 37 ◦C
or 30 min. Gel plugs were rehydrated with 10 ng/l trypsin in
0 mM ammonium bicarbonate for 45 min  at 4 ◦C and allowed
o incubate at 37 ◦C overnight. Post digestion 30 l 60% (v/v)
mmonium bicarbonate, 1% triﬂuroacetic acid was added to
he gel plugs and sonicated in an ultra-sonicating water bath
or 6 × 30 s bursts. Gel plugs were spun brieﬂy at 16,000 × g
nd the supernatant removed and placed into a new tube.
he addition of ammonium bicarbonate/triﬂuroacetic acid
ollowed by sonication was repeated and the supernatants
rom both repeats were pooled. Supernatants were dried in
 Maxi Dry Plus vacuum centrifuge (Hete-Holten A/S, Allerød, 3 ( 2 0 1 4 ) 85–99 87
Denmark) and resuspended in 10 l 1% (v/v) formic acid and
sent for MSMS analysis.
2.4.  Mass  spectrometry  and  protein  identiﬁcation
Samples prepared for liquid chromatography–tandem mass
spectrometry (LC–MS/MS) were analysed using electrospray
ionisation as previously reported [27,28]. Peptide mixtures
from trypsin digested gel spots were separated using a LC
Packings Ultimate nano-HPLC System. Sample injection was
via an LC Packings Famos auto-sampler and the loading sol-
vent was 0.1% formic acid. The pre-column used was a LC
Packings C18 PepMap 100, 5 mm,  100 A and the nano HPLC
column was a LC Packings PepMap C18, 3 mm,  100 A. The sol-
vent system was: solvent A (2% ACN with 0.1% formic acid),
and solvent B (80% ACN with 0.1% formic acid). The LC ﬂow
rate was 0.2 L/min with a gradient employed using 5% sol-
vent A to 100% solvent B in 1 h. The HPLC eluent was sprayed
into the nano-ES source of a Waters Q-TOFMS  via a New
Objective Pico-Tip emitter. The MS was operated in positive
ion mode and multiply charged ions were detected using a
data-directed MS/MS experiment. Collision induced dissocia-
tion (CID) MS/MS mass spectra were recorded over the mass
range m/z 80–1400 Da with scan time 1 s.
MassLynx v 3.5 (Waters, UK) ProteinLynx suite of tools
was used to process raw fragmentation spectra. Each
spectrum was combined and smoothed twice using the
Savitzky–Golay method at ±3 channels with background
noise subtracted at polynomial order 15 and 10% below
curve. Monoisotopic peaks were centred at 80% centroid
setting. Sequest compatible (.dta) ﬁle peak mass lists for
each spectrum were exported, and spectra common to
each 2DE spot were merged into a single MASCOT generic
format (.mgf) ﬁle using the on-line Peak List Conversion
Utility available at www.proteomecommons.org. Merged ﬁles
were submitted to a MASCOT MS/MS ions search within a
locally installed Mascot server (www.matrixscience.com)
to search an ‘in-house’ database constructed from
6260 (858 763 residues) F. hepatica EST sequences
downloaded and translated from the Sanger Institute
(ftp://ftp.sanger.ac.uk/pub/pathogens/fasciola/hepatica/ESTs/
Search parameters were as follows: enzyme set at trypsin
with one missed cleavage allowed; ﬁxed modiﬁcations
were set for carbamidomethylation with variable modiﬁca-
tions considered for set as the oxidation of methionine;
monoisotopic masses with unrestricted protein masses were
considered with peptide and fragment mass tolerances at
±1.2 Da and ±0.6 Da respectively for an ESI-QUAD-TOF instru-
ment. Protein identiﬁcations resulting from MASCOT ions
scores greater than 25 were considered as showing signiﬁ-
cant identity or extensive similarity (p < 0.05) to the predicted
identiﬁcation displayed (www.matrixscience.com).
Spectra that did not match any proteins, or scored non-
signiﬁcantly within F. hepatica EST database were re-searched
through MASCOT against the NCBI non-redundant database
(NCBI http://www.ncbi.nlm.nih.gov/nr release 20091112 con-
taining 10,032,801 sequences; 3,422,028,181 residues). MAS-
COT scores for individual ions greater than 23 indicated
signiﬁcant similarity whilst scores above 51 indicate signif-
icant identity or extensive similarity (p < 0.05). All MASCOT
o m i c s 3 ( 2 0 1 4 ) 85–99
Fig. 1 – F. hepatica survival and protein secretion under
TCBZ-SO stress (control 0 g/ml, sub-lethal 15 g/ml and
lethal 40 g/ml) (a) graphical view of F. hepatica survival
(expressed as %) in vitro maintenance under each TCBZ-SO
dose regime over the course of the experiment in hours (h).
Viable – ﬂuke expressing normal motility and appearance;
reduced viability – motility reduced, muscle tension and
morphological changes; non-viable – apparent death, no
motility and ﬂaccid musculature. (b) Cumulative protein
content (g) secreted/excreted from liver ﬂuke in vitro
maintenance under control, sub-lethal or lethal TCBZ-SO
conditions over time (h). Dashed lines in both (a) and (b)
indicate the addition of TCBZ-SO at the appropriate
concentration after 2 h in vitro culture.88  e u  p a o p e n p r o t e 
search parameters and settings were as described above
except that taxonomy was restricted to ‘Metazoa’ (1804634
sequences).
F. hepatica proteins identiﬁed via LC–MS/MS matching un-
annotated ESTs, were assigned putative identiﬁcation based
upon similarity to proteins with existing annotation within
GenBank non-redundant database (all non-redundant Gen-
Bank CDS translations + PDB + SwissProt + PIR + PRF exclud-
ing environmental samples from WGS  projects (9,636,254
sequences; 3,294,494,089 total letters: Posted date: Sep 2, 2009
5:42 PM;  Downloaded at ftp://ftp.ncbi.nih.gov/blast/db/).
3.  Results
3.1.  Survival
The viability of liver ﬂuke in vitro maintenance was assessed
at each change of media and was based on standard visible
motility of worms and worm shape [27]. All control samples
(Con) with the exception of one replicate showed 100% via-
bility after 26 h in vitro maintenance (Fig. 1a). The remaining
control replicate showed no motility in any of the 10 ﬂuke
post 26 h although all were alive post 14 h. All sub-lethal (SL)
samples showed 100% viability (Fig. 1A), although showed an
altered ‘curled and extended’ phenotype post maintenance.
Post 26 h in vitro maintenance all lethal (L) samples presented
with no motility and recorded as dead [27] (Fig. 1A). Survival for
all ‘lethal’ replicates declined rapidly post 8 h in maintenance
culture.
3.2.  ES  product  protein  content
Collected samples were assessed for their ES protein content
to identify trends as a response to TCBZ-SO treatment. Initial
protein release post 2 h incubation showed no signiﬁcant dif-
ferences between Con and SL and L treated samples (Fig. 1B).
Both treatment (TCBZ-SO Con, SL & L doses) (P2,71 = 0.043)
and time (P3,71 ≤ 0.001) had a signiﬁcant effect on the level of
protein expressed. There was a signiﬁcant treatment × time
interaction (P6,71 = 0.005) thereby demonstrating that the effect
of time on the level of protein expressed was dependent on the
treatment administered. In general, protein release decreased
over time in vitro maintenance. Notable differences were seen
post 14 and 26 h. At 14 h in maintenance culture, protein secre-
tion had dropped signiﬁcantly with control samples secreting
the most; Con > SL > L. Post 26 h, a large increase in released
protein was seen in the lethal samples only.
3.3.  ES  product  proteomic  arrays
Proteomic 2D arrays produced reproducible replicates among
treatments. Matching between treatment replicates was
between 50 and 75% with the average matching at 58.3%
(Supplementary Table 1). Only one set of replicates, sub-
lethal 14–26 h, failed to match within these limits and had a
low match percentage of 35%. This low percentage matching
relates to the low level of protein secreted by these worms,
often lower than 50 g in total (Fig. 1B). All replicate matches
and total spot numbers can be seen in Supplementary Table 2.After 2 h in vitro maintenance there was, as expected, low vari-
ation between treatments (all liver ﬂuke in control conditions
from 0 to 2 h; Supplementary Fig. 1). Thus, a high percentage
of replicate matching at this stage provided the conﬁdence
needed to assess two sets of replicates with TCBZ SO at SL
and L doses.
After 8 h only 1 protein spot (spot 13, Fig. 2 SL and L
2–8 h) showed a signiﬁcant change in abundance, a signiﬁ-
cant reduction with increasing TCBZ-SO concentrations (spot
13 F2,15 = 11.14, P = 0.001***) to complete absence in Lethal sam-
ples. In addition, a further protein spot was unique to SL and
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 85–99 89
Fig. 2 – Representative 2DE SDS-PAGE arrays of F. hepatica ES products under TCBZ-SO stress at sub-lethal (SL) and lethal (L)
concentrations (15 and 50 g/ml, respectively) over three time periods, 2–8 h, 8–14 h and 14–26 h. TCBZ-SO induced ES
products were  proﬁled on 12.5% polyacrylamide gels and stained with coomassie blue. Proteins were  isoelectric focused on
17 cm pH 3–10 linear immobilised pH gradient (IPG) strips. Circled spots correspond to those proteins consistently present
on averaged gels for each treatment. Numbered protein spots, in conjunction with Table 1, correspond to abundance
changes compared to control ES products at the corresponding time point and their putative protein identiﬁcations can be
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 treatments (spot 1, Fig. 2). Lethal samples also showed an
dditional unique spot (Fig. 2, spot 19).
Post 14 h in vitro maintenance the majority of changes
esulting from in vitro treatment with TCBZ-SO were seen. A
otal of 22 protein spots (Fig. 2 SL and L 8–14 h spots 1, 4–11,
3–14, 16–17 and 20–27 [excluding 26A and D]) showed sig-
iﬁcant variation between treatments. Of the 22 signiﬁcant
pots, 11 normalised spot volumes were consistent between
on and SL samples. The signiﬁcant variation observed was
hen comparing L samples to Con and SL, showing sig-
iﬁcant reductions in these protein spots (spots 4–11, 14
nd 16–17; see Supplementary Table 3 for spot differential
bundance statistics). The remaining 11 signiﬁcant spots,with the exception of spot 13, were additional/unique pro-
tein spots when compared to Con samples; spots 1, 20 and
21 for SL and 1 and 22–27 (excluding 26 A and D) for L
samples. The ﬁnal spot of signiﬁcant change was that of
spot 13 reduced in abundance to absence in both SL and L
samples.
Samples in vitro maintenance post 26 h showed signiﬁcant
variation relating to levels of TCBZ-SO. A total of 27 protein
spots (Fig. 2 and Table 1) varied in abundance with 17 of these
(spots 2–15, 18 and 30A and B) changing with increasing levels
of TCBZ-SO in both SL and L samples. The remaining 10 spots
(Fig. 2, spots 1, 26A–D, 28–29 and 31–33) were additional/unique
protein spots when compared to Con samples with all, with
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Table 1 – Putative protein identiﬁcations of F. hepatica TCBZ-SO induced ES products using MASCOT. Spectra from mass spectrometry were  subjected to MSMS ion
searches using MASCOT (Matrix Science) searching an in house EST database. Signiﬁcant hits, at P = 5%, have a MASCOT score of 25 or greater. All signiﬁcant EST hits
were then subjected to BLAST analysis against GenBank to assign an identity to matching ESTs. Therefore, all reported accession numbers are from GenBank.
Spot number MS/MS  ion search Highest scoring BLAST hit within GenBank Protein Variationa
F. hepatica EST hit MASCOT
score
Peptides
matched
Protein Organism Accession
number
E-value 2–8 h 8–14 h 14–26 h
1 NS – – – – – – SL, L SL, L SL
2 Fhep43c03.q1k 53 2 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−108 L−b
Fhep06c12.q1k 52 1 Cathepsin L (CL5) F.  hepatica AAF76330 1.00E-112
Fhep44h05.q1k 52 1 Cathepsin L (CL5) F.  hepatica AAF76330 1.00E−116
Fhep55g09.q1k 52 1 Cathepsin L (CL5) F.  hepatica AAF76330 1.00E−135
3 Fhep43c03.q1k 356 14 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 3.94E−106 SL−  L−b
Fhep54d04.q1k 356 14 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 4.07E−110
Fhep42b08.q1k 207 9 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−127
Fhep48f01.q1k 207 9 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−114
Fhep48f09.q1k 191 6 Cathepsin L-Like
Protease (CL2)
F.  hepatica CAA80446 1.00E−119
Fhep38a03.q1k 191 7 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−146
4 Fhep43c03.q1k 345 15 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 3.94E−106 L− SL−  L− −
Fhep35b02.q1k 214 9 Cathepsin L1D (CL1D) F. hepatica ACJ12893/4 1.00E−70
Fhep35d02.q1k 214 9 Cathepsin L1D (CL1D) F. hepatica ACJ12894 3.00E−83
Fhep47f09.q1k 214 9 Cathepsin L1D (CL1D) F. hepatica ACJ12893/4 1.00E−66
Fhep42b08.q1k 152 9 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−127
5 Fhep07e08.q1k 173 9 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−119 L− L−
Fhep39a05.q1k 103 8 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−138
Fhep47g05.q1k 34 1 Cathepsin L (CL5) F. gigantica ABV90500 9.00E−39
HAN5016f11.q1kT3 34 1 Cathepsin L (CL5) F. gigantica ABV90500 1.00E−64
Fhep40g12.q1k 32 3 NS – – –
6 Fhep07e08.q1k 144 7 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−119 L−b L−b
Fhep37h07.q1k 144 7 Cathepsin L (CL5) F.  hepatica AAF76330 1.00E−120
HAN5020e07.p1kT7 67 4 Cathepsin L (CL1A) F. hepatica AAM11647 1.00E−138
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7 Fhep07e08.q1k 153 5 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−119 L− L−
Fhep37h07.q1k 153 5 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−120
Fhep10h09.q1k 153 5 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−110
Fhep44a04.q1k 101 6 Cathepsin L (CL1D) F. gigantica ABV90502 9.00E−77
8 Fhep20f07.q1k 258 9 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 6.00E−84 SL+ L− L−
Fhep47e11.q1k 258 9 Cathepsin L protein
(CL1A)
F.  hepatica AAR99518 2.00E−95
Fhep54a06.q1k 258 9 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 8.00E−84
Fhep45a09.q1k 240 10 Cathepsin L-like
proteinase (CL1A)
F.  hepatica Q24940 5.00E−93
Fhep44h04.q1k 205 10 Cathepsin L protein
(CL1A/B)
F.  hepatica AAR99519 1.00E−112
9 Fhep11e04.q1k 93 4 Cathepsin L1D (CL1D) F.  hepatica ACJ12894 2.00E−85 L− SL−  L−
Fhep21a11.q1k 93 4 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−106
Fhep41d11.q1k 93 4 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−99
10 Fhep21a11.q1k 288 12 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−106 L− SL−  L− −
Fhep41d11.q1k 288 12 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−99
11 Fhep45a09.q1k 149 9 Cathepsin L-like
proteinase (CL1A)
F.  hepatica Q24940 5E−93 L− SL−  L− −b
12 Fhep20f07.q1k 373 14 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 6.00E−84 SL−  L−
13 Fhep20f07.q1k 401 12 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 6.00E−84 SL− L−b SL−b L−b SL−b L−b
Fhep47e11.q1k 401 12 Cathepsin L protein
(CL1A)
F.  hepatica AAR99518 2.00E−95
Fhep54a06.q1k 401 12 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 8.00E−84
14 Fhep20f07.q1k 137 5 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 6.00E−84 L− L−b
Fhep47e11.q1k 137 5 Cathepsin L protein
(CL1A)
F.  hepatica AAR99518 2.00E−95
Fhep54a06.q1k 137 5 Secreted cathepsin L1
(CL1A)
F.  hepatica AAB41670 8.00E−84
15 Fhep11e04.q1k 135 6 Cathepsin L1D (CL1D) F. hepatica ACJ12894 2.00E−85 SL−  L−
Fhep21a11.q1k 135 6 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−106
Fhep41d11.q1k 135 6 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−99
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Table 1 – (Continued)
Spot number MS/MS ion search Highest scoring BLAST hit within GenBank Protein Variationa
F. hepatica EST hit MASCOT
score
Peptides
matched
Protein Organism Accession
number
E-value 2–8 h 8–14 h 14–26 h
16 Fhep07d09.q1k 235 7 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 1.00E−105 L−b
Fhep45a09.q1k 235 7 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 5.00E−93
Fhep47g04.q1k 235 7 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 5.00E−83
Fhep20f07.q1k 205 7 Secreted cathepsin L1
(CL1A)
F. hepatica AAB41670 6.00E−84
Fhep47e11.q1k 205 7 Cathepsin L protein
(CL1A)
F. hepatica AAR99518 2.00E−95
Fhep43c04.q1k 205 7 Secreted cathepsin L1
(CL1A)
F. hepatica AAB41670 2.00E−83
17 Fhep20f07.q1k 145 7 Secreted cathepsin L1
(CL1A)
F. hepatica AAB41670 6.00E−84 L−
Fhep47e11.q1k 145 7 Cathepsin L protein
(CL1A)
F. hepatica AAR99518 2.00E−95
Fhep54a06.q1k 145 7 Secreted cathepsin L1
(CL1A)
F. hepatica AAB41670 8.00E−84
Fhep36f11.q1k 60 2 Thioredoxin Peroxidase F. gigantica ABY85785 1.00E−107
18 Fhep05a08.q1k 54 1 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 6.00E−64 SL+ L−b
Fhep46a02.q1k 54 1 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 1.00E−101
Fhep35d02.q1k 54 1 Cathepsin L1D (CL1D) F. hepatica ACJ12894 3.00E−83
Fhep43c03.q1k 50 2 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 3.94E−106
Fhep54d04.q1k 50 2 Secreted cathepsin L2
(CL2)
F. hepatica ABQ95351 4.07E−110
19 NS – – – – – – L
20 Fhep10b05.q1k 78 2 Cathepsin L1D (CL1D) F. hepatica ACJ12894 4.00E−70 SL
Fhep21a11.q1k 78 2 Cathepsin L1D (CL1D) F. hepatica ACJ12894 1.00E−106
Fhep46e07.q1k 78 2 Cathepsin L1D (CL1D) F. hepatica ACJ12894 2.00E−99
Fhep50d05.q1k 30 3 Protein Disulphide
Isomerase
F.  hepatica CAA12644 1.00E−151
Fhep37e03.q1k 28 2 SJCHGC06296 Protein S. japonicum AAW25214 2.00E−27
Fhep37e03.q1k 28 2 Similar to NM 003344
Ubiquitin-Conjugating
Enzyme E2H in Mus
musculus
S. mansoni AAP06436 3.00E−27
Fhep22a12.q1k 27 1 Coatomer Gamma
Subunit
S.mansoni XP 002580249 2.00E−96
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21 Fhep05c11.q1k 97 1 Cathepsin L1D (CL1D) F. hepatica ACJ12893 4.00E−46 SL
Fhep13h03.q1k 97 1 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 1.00E−84
Fhep25g09.q1k 97 1 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 1.00E−124
22 NS – – – – – – L
23 NS – – – – – – L
24 NS – – – – – – L
25 NS – – – – – – L
26A Fhep45a09.q1k 106 2 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 5.00E−93 L
Fhep40g02.q1k 103 2 Cathepsin L-Like (CL1B) F. hepatica AAK38169 1.00E−23
HAN4008f12.q1kT3 95 6 Gelsolin S. mansoni XP 002572344 2.00E−74
26B HAN4008f12.q1kT3 128 6 Gelsolin S. mansoni XP 002572344 2.00E−74 L L
Fhep09a08.q1k 124 6 Actin S. mansoni XP 002575979 1.00E−111
Fhep22a04.q1k 90 6 Actin S. mansoni XP 002578518 1.00E−104
Fhep34c01.q1k 87 3 Actin Stictodora lari AAS20346 4.00E−79
HAN3008-1g11.q1k 72 4 Actin S. mansoni XP 002578518 1.00E−123
26C Fhep09a08.q1k 151 6 Actin S. mansoni XP 002575979 1.00E−111 L L
HAN3008-1g11.q1k 44 6 Actin S. mansoni XP 002578518 1.00E−123
Fhep22a04.q1k 44 3 Actin S. mansoni XP 002578518 1.00E−104
HAN4003e07.p1kT7 32 1 Actin S. mansoni XP 002578518 1.00E−40
HAN4003e07.q1kT3 32 1 SJCHGC06318 Protein S. japonicum AAW25537 1.00E−75
HAN4008a06.p1kT7 32 1 SJCHGC06318 Protein S. japonicum AAW25537 6.00E−70
HAN4008a06.p1kT3 32 1 Actin S. mansoni XP 002578518 5.00E−71
HAN5015g10.q1kT3 32 1 SJCHGC06318 Protein S. japonicum AAW25537 3.00E−62
26D Fhep34c01.q1k 98 2 Actin Stictodora lari AAS20346 4.00E−79 L
Fhep09a08.q1k 97 4 Actin S. mansoni XP 002575979 1.00E−111
HAN4003e07.p1kT7 58 2 Actin S. mansoni XP 002578518 1.00E−40
HAN4003e07.q1kT3 58 2 SJCHGC06318 Protein S. japonicum AAW25537 1.00E−75
HAN4008a06.p1kT7 58 2 SJCHGC06318 Protein S. japonicum AAW25537 6.00E−70
HAN4008a06.p1kT3 58 2 Actin S. mansoni XP 002578518 5.00E−71
HAN5015g10.q1kT3 58 2 SJCHGC06318 Protein S. japonicum AAW25537 3.00E−62
HAN3008-1g11.q1k 51 6 Actin S. mansoni XP 002578518 1.00E−123
27 Fhep15d10.q1k 60 2 Glyceraldehyde-3-
phosphate
dehydrogenase
F.  hepatica AAG23287 2.00E−82 L
28 Fhep07e08.q1k 131 4 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−119 L
Fhep10h09.q1k 131 4 Cathepsin L (CL5) F. hepatica AAF76330 1.00E−110
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Table 1 – (Continued)
Spot number MS/MS ion search Highest scoring BLAST hit within GenBank Protein Variationa
F. hepatica EST hit MASCOT
score
Peptides
matched
Protein Organism Accession
number
E-value 2–8 h 8–14 h 14–26 h
29 Fhep07d09.q1k 120 2 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 1.00E−105 L
Fhep45a09.q1k 120 2 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 5.00E−93
Fhep47g04.q1k 120 2 Cathepsin L-like
proteinase (CL1A)
F. hepatica Q24940 5.00E−83
30A Fhep28b10.q1k 147 7 Enolase F. hepatica AAA57450 1.00E−91  L+
30B Fhep28b10.q1k 147 7 Enolase F. hepatica AAA57450 1.00E−91  SL+, L++
31 NS – – – – – – L
32 Fhep26g11.q1k 137 4 Multivalent Antigen
sjTPI-97
Synthetic
Construct
ABS19444 7.00E−89  L
Fhep26g11.q1k 137 4 Triose-Phosphate
Isomerase
Orientobilharzia
turkestanicum
AAZ57433 6.00E−87
33 Fhep05f07.q1k 97 4 SJCHGC05973 Protein
(DJ-1)
S. japonicum AAW26651 3.00E−54  L
HAN4008f12.p1kT7 74 2 SJCHGC06031 Protein S. japonicum AAX25657 3.00E−66
HAN4008f12.q1kT3 74 2 Gelsolin S. mansoni XP 002572344 2.00E−74
Fhep29e10.q1k 37 3 GJ21252 (Cyclophilin) Drosophila
virilis
XP  002048823 4.00E−56
a When compared to control ES products, at the corresponding time point, protein spots showing a change in abundance are denoted. If a unique protein spot is found in the sub-lethal (TCBZ-SO
at 15 g/ml) ES products they are denoted with SL. If a unique protein spot is found in the lethal (TCBZ-SO at 50 g/ml) ES products they are denoted with L. If followed by + − they are not unique
compared to controls but are more than 2-fold up/down regulated.
b Denotes an absence of the protein spot from the array compared to control (TCBZ-SO at 0 g/ml) ES products. Those indications shaded in grey were identiﬁed as 2-fold up/down regulated but not
statistically signiﬁcant, see also Supplementary Table 3 for all statistics. Full peptide identiﬁcations following MSMS can be found in Supplementary Table 4.
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Fig. 3 – Evidence for the putative identiﬁcation of calreticulin. (a) MSMS  spectra from the analysis of a 2+ peptide m/z 752.78
(sequence FGPDICGFDIK) sequenced from protein spot 1 (Fig. 2 and Table 1), identiﬁed as calreticulin-3 of Saimiri boliviensis.
Predicted residues shaded in grey highlight amino acids that do not match  with a F. hepatica Contig. Sequencing was
performed automated using MassLynx v 3.5. (b) Multiple alignment of calreticulin from S. boliviensis (XP 003942378), the
matching F. hepatica transcript (Fh Contig21931) and the sequence derived from tandem mass spectrometry (MSMS). Amino
acid residues boxed in black represent 100% matching among sequences. Black arrows indicate the start and end of the
sequence tag identiﬁed from tandem mass spectrometry. The grey arrow indicates the start of the matching theoretical
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he exception of spot 1, unique to L samples. All spot variations
an be seen in Table 1.
.4.  Protein  identiﬁcation
ll 33 protein spots of interest highlighted by 2D arrays were
nalysed by MSMS  (Table 1). Of these 33, only 7 could not
e identiﬁed using MSMS  ion scans with an in-house EST
atabase and matching ESTs to a Genbank entry. The greatest
umber of identiﬁcations was F. hepatica cathepsin L proteases
ith 22 protein spots. The majority of these identiﬁcations
ere from spots reduced in abundance, and ultimate absence,
f Cathepsin L proteases in L samples after 14 and 26 h in vitro
aintenance.Of particular interest were spots 26A–D, identiﬁed as actin
and gelsolin, appearing in ES samples after 14 and 26 h in vitro
maintenance at L levels only and spots 30A and B, identi-
ﬁed as enolase, increasing in abundance after 26 h in both
SL and L in vitro maintenance cultures. Also identiﬁed only
in L in vitro maintenance after 26 h were triose phosphate
isomerase and DJ-1 (Fig. 2 and Table 1 spots 32 and 33, respec-
tively).
Of the seven protein spots unidentiﬁed by MSMS ion scans
spot 1 appeared to be of signiﬁcant interest. Spot 7 was iden-
tiﬁed in response to TCBZ-SO exposure after 8, 14 and 26 h
in vitro maintenance in SL samples and after 8 and 14 h in
L samples. In order to identify this protein MSMS spectra
from replicate samples were de novo sequenced. This repeat-
edly identiﬁed a 2+ peptide of m/z 752.78 and sequenced
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Fig. 4 – Dimension plots from random forest analysis of ES product proteomes using normalised spot volumes for control
(Con: black closed squares), sub-lethal (SL: black closed triangles) and lethal (L: black closed circles) TCBZ-SO regimes.
Dimension plots are from ES products after 2 h (a), 8 h (b), 14 h (c) and 26 h (d). Dashed lines represent separation between
drug exposed and control samples. Separation between control samples and TCBZ-SO exposed samples occurs after 8 h
6 h iwith almost complete separation of treatment groups after 2
as FGPDICGFDIK (Fig. 3A). When using BLAST to assign a
putative identiﬁcation to this peptide calreticulin-3 (Genbank:
XP 003942378 Organism: Saimiri boliviensis Coverage: 100% E
value: 0.004) was hit. The resulting sequence was used to
search a F. hepatica transcriptome database (EBI-ENA archive
ERP000012: an initial characterisation of the F. hepatica trans-
criptome using 454-FLX sequencing) for a Fasciola speciﬁc
sequence. When a matching contig (Contig21931) was com-
pared to the de novo sequenced peptide, three amino acid
residues were not consistent between the two sequences
(Fig. 3B) despite good sequence similarity between the F. hepat-
ica sequence and the S. boliviensis sequence over this small
region (Amino acid residues 83–93; XP 003942378 numbering).
However, the quality of the MSMS  generated mass spectrum
spanning these three amino acid residues (Fig. 3A shadedn vitro maintenance.
in grey) was repeatedly low making de novo interpretation of
these three residues challenging.
3.5.  Random  forests  (RF)  analysis
After subjecting F. hepatica to TCBZ-SO exposure in vitro main-
tenance, RF analysis was performed to assess the impact of
the 2D protein arrays and the ability to distinguish between
TCBZ-SO treatment proteomes; namely Con, SL or L TCBZ-SO
regimes. Post 2 h in vitro maintenance, no distinct separation
of treatment groups could be identiﬁed corresponding to a low
clustering coefﬁcient (clustering coefﬁcient 0–2 h = 0.44) seen
in the resulting dimension plots (Fig. 4A). This was despite of
increasing RF tree numbers to 100,000 thereby encompassing
all variables (protein spots).
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As early as 8 h in maintenance a distinction between Con
nd TCBZ-SO exposed samples (SL and L) is almost appar-
nt (Fig. 4B). However, there was no separation between SL
nd L samples again related to a low clustering coefﬁcient
2–8 h = 0.48). At 8–14 h samples begin to discriminate into
hree clusters associated with treatment, Con, SL and L doses
clustering coefﬁcient 8–14 h = 0.53) still with a deﬁned sepa-
ation between Con and TCBZ-SO exposed samples (Fig. 4C).
fter 14–26 h in vitro maintenance, clear separation between
roups can be identiﬁed again based on treatment (Fig. 4D:
lustering coefﬁcient 14–26 h = 0.67).
.  Discussion
e  have shown measurable differences in the released pro-
ein signature of adult F. hepatica when TCBZ-SO exposed and
illed, suggesting that potential biomarkers are released into
he host environment to determine TCBZ resistance and sus-
eptibility. In addition, we have identiﬁed a protein signature
eleased by F. hepatica during in vitro exposure to a sub-lethal
ose of drug, a potentially new approach to measure drug fail-
re in the ﬁeld as a consequence of sub-optimal or incorrect
osing.
We have also identiﬁed the multifunctional Ca2+ binding
rotein calreticulin (CRT) as a new biomarker of TCBZ-SO
xposure and survival as judged by post-proteomic image
nalysis and RF analysis i.e. only liver ﬂuke exposed to TCBZ-
O, at both studied concentrations (SL and L), that were alive
eleased CRT into ES products. Those that had died at a lethal
ose of TCBZ-SO after 26 h ceased to release CRT into the ES
roducts. CRT from parasitic helminths has a variety of sug-
ested functions [29–31]. However, perhaps more  signiﬁcant is
he ﬁnding of CRT in the interaction of other helminths and
nthelmintic compounds.
Mutapi et al. [32] studying the related S. haematobium
bserved that CRT was recognised by human sera following
nfection and subsequent treatment with praziquantel (PZQ).
herefore, does CRT have a similar role in both TCBZ-SO and
ZQ exposure and/or is it a novel generic biomarker of ﬂat-
orm drug response. It has been shown in parasitic species
hat increases in CRT levels can be activated by a variety of
iological or, more  pressing, chemical stressors [33]. It is likely
hat the recognised protein chaperoning function of CRT (Gene
ntology terms – GO: 0006457 Protein folding and GO: 0051082
nfolded protein binding), preventing aggregation of unfolded
roteins [34], is the primary reason for an increase following
tress. However, regarding anthelmintic stress, it is suspected
hat PZQ increases membrane permeability to cations, such
s Ca2+ [35]. As a result, an increase in CRT expression may be
n attempt to reduce store operated Ca2+ inﬂux [36] in order to
alance Ca2+ homeostasis [34,37]. It is therefore possible that
CBZ-SO exposure in Fasciola may also affect Ca2+ homeosta-
is.
Alternatively, in the current study, increased CRT released
nto ES products may also result from xenobiotic induced
ecrosis from incorrect Ca2+ homeostasis – show in C. ele-
ans for stressors not affecting Ca2+ inﬂux across the plasma
embrane [38]. 3 ( 2 0 1 4 ) 85–99 97
Aside from CRT, the cathepsin L (Cat L) proteases were also
revealed as signiﬁcant in determining TCBZ-SO exposure and
correct drug dosing and drug failure. The Cat L proteases con-
tribute signiﬁcantly to the ES products of F. hepatica [21,39],
with family members continually secreted and regurgitated
into the host environment. Therefore, a change in abundance
of this important family of virulence proteins, in relation to
TCBZ-SO exposure, would be expected. Indeed, a reduction
in the viability of ﬂukes exposed to TCBZ-SO was observed
with a concomitant decrease in Cat L protease release; results
comparable with studies on levamisole treated H. contortus
revealing a 50% reduction of Cat L proteases post treatment
[40].
The glycolytic enzyme enolase can be readily found in ES
products of F. hepatica [21,41] or associated with membrane
fractions [42,43], but here we have identiﬁed enolase as an
ES product determinant of TCBZ-SO exposure; up-regulated
in ES products after 26 h in both SL and L treatments. We
have also previously shown that enolase is increased in cyto-
solic samples in response to TCBZ-SO exposure [27] suggesting
increased enolase abundance may be a general response to
xenobiotic exposure. Indeed, work by Cornish and Bryant
[44] observed an increase of energy metabolising products
post stimulation with benzimidazole drugs further suggesting
increased enolase abundance may be a general anthelmintic
response.
Finally, four proteins, actin, gelsolin, DJ-1 and triose phos-
phate isomerise (Tpi), were identiﬁed as potential biomarkers
of TCBZ-SO terminating ﬂuke, rather than biomarkers of
simply TCBZ-SO exposure. All of these proteins have been
found previously associated with the tegument [42,43] and
all, with the exception of DJ-1, have been identiﬁed in ES
products [see 42]. Upon reductions in ﬂuke viability, and
ultimately death, more  components associated with the
tegument are released into ES products [21], an observation
also seen in other ﬂukes; both S. haematobium actin and
Tpi revealed post PZQ treatment [32]. Therefore, these sub
tegumental/tegumental associated proteins may become
suitable markers for measuring the death of F. hepatica.
Fasciola Glutathione transferases (GST) are a recognised
component of in vitro ES products. Both Sigma and Mu
class GSTs have been identiﬁed in adult and juvenile ES
products [43,45,46]. Interestingly, GSTs have also been impli-
cated in the TCBZ-SO response in F. hepatica. In particular,
Chemale et al. [27] identiﬁed a Mu  class GST responding
as a result of TCBZ-SO exposure and the study of She-
hab et al. [47] observed greater levels of GST activity as
a result of TCBZ-SO treatment. Despite these ﬁndings, no
GSTs were identiﬁed in the current study. However, the two
previous studies were investigating cytosolic responses and
GSTs only contribute a small proportion to the total ES prod-
ucts.
An important consideration, in in vitro maintenance stud-
ies such as this, is the TCBZ-SO susceptibility/resistance status
of the liver ﬂuke used. In the current study, the liver ﬂuke
used were of ‘wild-type’ susceptibility. Thus, the two response
proﬁles identiﬁed can relate to ‘wild-type’ susceptibility. Fol-
lowing on from the current study it will be prudent to assess
the ﬁngerprint response proﬁles of deﬁned liver ﬂuke TCBZ-
SO resistant isolates. There is then the possibility to identify
o m i c
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a third subset of potential biomarkers – markers of TCBZ-SO
resistance.
5.  Conclusions
Two panels of F. hepatica proteins have been identiﬁed in the
current study; TCBZ-SO survival markers (CRT, Cat L pro-
teases and enolase) and conﬁrmed TCBZ-SO killing markers
(actin, gelsolin, DJ-1 and Tpi). Therefore, this study provides
several new F. hepatica protein candidates for validation in
diagnostic testing of TCBZ response (measuring drug failure
or resistance). These new ES markers need to be conﬁrmed
as identiﬁable in infected host faeces, as either intact or
fragmented proteins by antibody detection. This proteomic
lead approach is transferable to other parasitic or microbial
systems for the identiﬁcation of biomarkers for antimicro-
bial/anthelmintic action.
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